权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Follow on Deployment and Development of a Machine Learning/AI Cancer Rule-Out Test for the NHS Two Week Wait Pathway

跟进 NHS 两周等待途径的机器学习/人工智能癌症排除测试的部署和开发

基本信息

批准号：
830203
负责人：
金额：
$ 182.97万
依托单位：
PINPOINT DATA SCIENCE LIMITED
依托单位国家：
英国
项目类别：
Innovation Loans
财政年份：
2021
资助国家：
英国
起止时间：
2021 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=830203
关键词：
Follow Deployment Development Machine Learning

项目摘要

Our ambition is to distill the vast and ever increasing complexity of medical data and research into simple tools enabling clinicians to make better choices for their patients.Earlier diagnosis is critical to increasing the cancer survival rate so patients can receive treatment when there is a better chance of achieving a complete cure. In 2018 PinPoint began developing a test to quickly triage patients with symptoms to help clinicians reduce patient anxiety and time to diagnosis.Working with clinicians and academics we have created the PinPoint(r)? Test. It uses machine learning to combine signals from multiple blood analytes and basic patient information into a single clinical decision support tool. This allows clinicians to easily identify those patients who should be referred to specialists for cancer diagnosis, red flag particularly urgent cases and identify those who can be safely investigated for other possible causes of their symptoms.With support from Innovate UK PinPoint has been building the evidence base by evaluating the service in the NHS, preparing for wider adoption and developing upgrades for the future.Earlier diagnosis is critical to increasing the cancer survival rate so patients can receive treatment when there is a better chance of achieving a complete cure. In 2018 PinPoint began developing a test to quickly triage patients with symptoms to help clinicians reduce patient anxiety and time to diagnosis.Working with clinicians and academics we have created the PinPoint(r)? Test. It uses machine learning to combine signals from multiple blood analytes and basic patient information into a single clinical decision support tool. This allows clinicians to easily identify those patients who should be referred to specialists for cancer diagnosis, red flag particularly urgent cases and identify those who can be safely investigated for other possible causes of their symptoms.With support from Innovate UK PinPoint has been building the evidence base by evaluating the service in the NHS, preparing for wider adoption and developing upgrades for the future.

我们的目标是将庞大且日益复杂的医疗数据和研究提炼成简单的工具，使临床医生能够为患者做出更好的选择。早期诊断对于提高癌症生存率至关重要，以便患者在有更好的机会实现完全治愈时可以接受治疗。 2018 年，PinPoint 开始开发一种测试，以快速对有症状的患者进行分类，以帮助临床医生减少患者焦虑并缩短诊断时间。我们与临床医生和学者合作创建了 PinPoint(r)?测试。它使用机器学习将多种血液分析物的信号和基本患者信息组合到一个临床决策支持工具中。这使得临床医生能够轻松识别那些应该转诊给专家进行癌症诊断的患者，对特别紧急的病例发出危险信号，并识别那些可以安全地调查其症状的其他可能原因的患者。在 Innovate UK 的支持下，PinPoint 一直在通过评估 NHS 的服务来建立证据基础，为未来更广泛的采用和开发升级做好准备。早期诊断对于提高癌症生存率至关重要，以便患者在有更好机会时可以接受治疗达到彻底治愈的目的。 2018 年，PinPoint 开始开发一种测试，以快速对有症状的患者进行分类，以帮助临床医生减少患者焦虑并缩短诊断时间。我们与临床医生和学者合作创建了 PinPoint(r)?测试。它使用机器学习将多种血液分析物的信号和基本患者信息组合到一个临床决策支持工具中。这使得临床医生能够轻松识别那些应该转诊给专家进行癌症诊断的患者，对特别紧急的病例发出危险信号，并识别那些可以安全地调查其症状的其他可能原因的患者。在 Innovate UK 的支持下，PinPoint 一直在通过评估 NHS 的服务来建立证据基础，为更广泛的采用和开发未来的升级做好准备。